View of Using CRISPR-X for Optimization of Antibodies Towards A30P α-synuclein Oligomers in Immunotherapy of Parkinson’s Disease

Return to Article Details Using CRISPR-X for Optimization of Antibodies Towards A30P α-synuclein Oligomers in Immunotherapy of Parkinson’s Disease Download Download PDF